Multicatheter interstitial brachytherapy versus stereotactic radiotherapy with CyberKnife for accelerated partial breast irradiation: a comparative treatment planning study with respect to dosimetry of organs at risk.
Brachytherapy
/ instrumentation
Breast
/ radiation effects
Catheters
/ statistics & numerical data
Female
Fiducial Markers
Heart
/ radiation effects
Humans
Lung
/ radiation effects
Organs at Risk
/ radiation effects
Radiation Dosage
Radiation Injuries
/ prevention & control
Radiometry
/ instrumentation
Ribs
/ radiation effects
Skin
/ radiation effects
Tumor Burden
Unilateral Breast Neoplasms
/ diagnostic imaging
APBI
CyberKnife
dosimetric comparison
multicatheter interstitial brachytherapy
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
25 03 2021
25 03 2021
Historique:
received:
27
08
2020
accepted:
02
02
2021
pubmed:
27
3
2021
medline:
16
9
2021
entrez:
26
3
2021
Statut:
epublish
Résumé
The aim of the study was to dosimetrically compare multicatheter interstitial brachytherapy (MIBT) and stereotactic radiotherapy with CyberKnife (CK) for accelerated partial breast irradiation (APBI) especially concerning the dose of organs at risk (OAR-s). Treatment plans of thirty-two MIBT and CK patients were compared. The OAR-s included ipsilateral non-target and contralateral breast, ipsilateral and contralateral lung, skin, ribs, and heart for left-sided cases. The fractionation was identical (4 x 6.25 Gy) in both treatment groups. The relative volumes (e.g. V100, V90) receiving a given relative dose (100%, 90%), and the relative doses (e.g. D0.1cm Regarding non-target breast CK performed slightly better than MIBT (V100: 0.7% The target volume can be properly irradiated by both techniques with similar dose distributions and high dose conformity. Regarding the dose to the non-target breast, heart, and contralateral organs the CK was superior, but the nearby organs (skin, ribs, ipsilateral lung) received less dose with MIBT. The observed dosimetric differences were small but significant in a few parameters at the examined patient number. More studies are needed to explore whether these dosimetric findings have clinical significance.
Sections du résumé
BACKGROUND
The aim of the study was to dosimetrically compare multicatheter interstitial brachytherapy (MIBT) and stereotactic radiotherapy with CyberKnife (CK) for accelerated partial breast irradiation (APBI) especially concerning the dose of organs at risk (OAR-s).
PATIENTS AND METHODS
Treatment plans of thirty-two MIBT and CK patients were compared. The OAR-s included ipsilateral non-target and contralateral breast, ipsilateral and contralateral lung, skin, ribs, and heart for left-sided cases. The fractionation was identical (4 x 6.25 Gy) in both treatment groups. The relative volumes (e.g. V100, V90) receiving a given relative dose (100%, 90%), and the relative doses (e.g. D0.1cm
RESULTS
Regarding non-target breast CK performed slightly better than MIBT (V100: 0.7%
CONCLUSIONS
The target volume can be properly irradiated by both techniques with similar dose distributions and high dose conformity. Regarding the dose to the non-target breast, heart, and contralateral organs the CK was superior, but the nearby organs (skin, ribs, ipsilateral lung) received less dose with MIBT. The observed dosimetric differences were small but significant in a few parameters at the examined patient number. More studies are needed to explore whether these dosimetric findings have clinical significance.
Identifiants
pubmed: 33768766
pii: raon-2021-0016
doi: 10.2478/raon-2021-0016
pmc: PMC8042824
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-239Informations de copyright
© 2021 András Herein, Gábor Stelczer, Csilla Pesznyák, Georgina Fröhlich, Viktor Smanykó, Norbert Mészáros, Csaba Polgár, Tibor Major, published by Sciendo.
Références
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Brachytherapy. 2011 Sep-Oct;10(5):421-6
pubmed: 21353647
Med Dosim. 2014 Summer;39(2):152-8
pubmed: 24480375
J Contemp Brachytherapy. 2020 Apr;12(2):166-174
pubmed: 32395141
Radiother Oncol. 2006 Jun;79(3):321-8
pubmed: 16730085
Front Oncol. 2014 Oct 22;4:284
pubmed: 25374841
Front Oncol. 2020 Apr 29;10:672
pubmed: 32411612
Rep Pract Oncol Radiother. 2012 Jun 15;17(4):200-6
pubmed: 24377024
Radiat Oncol. 2010 Oct 04;5:90
pubmed: 20920346
Strahlenther Onkol. 2017 May;193(5):367-374
pubmed: 28044202
Lancet Oncol. 2018 Jun;19(6):834-844
pubmed: 29695348
Radiother Oncol. 2015 Dec;117(3):477-82
pubmed: 26438972
Strahlenther Onkol. 2019 Oct;195(10):861-871
pubmed: 31321461
Brachytherapy. 2005;4(2):121-9
pubmed: 15893265
Lancet Oncol. 2017 Feb;18(2):259-268
pubmed: 28094198
Lancet. 2016 Jan 16;387(10015):229-38
pubmed: 26494415
Radiother Oncol. 2017 Jan;122(1):17-23
pubmed: 27544819
Radiother Oncol. 2013 Aug;108(2):197-202
pubmed: 23742961
Technol Cancer Res Treat. 2016 Jun;15(3):437-45
pubmed: 26335703
Radiother Oncol. 2016 Jul;120(1):119-23
pubmed: 27422584
Brachytherapy. 2021 Mar-Apr;20(2):332-338
pubmed: 33223449
Radiother Oncol. 2016 Jan;118(1):199-204
pubmed: 26776444
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):296-302
pubmed: 18086392
Lancet. 2019 Dec 14;394(10215):2155-2164
pubmed: 31813636
Brachytherapy. 2021 Mar-Apr;20(2):326-331
pubmed: 33221260
Brachytherapy. 2020 Mar - Apr;19(2):264-274
pubmed: 31787575
Eur J Cancer Care (Engl). 2014 Jan;23(1):51-64
pubmed: 23947545
Strahlenther Onkol. 2019 Apr;195(4):310-317
pubmed: 30603857
Radiother Oncol. 2010 Mar;94(3):264-73
pubmed: 20181402
Gland Surg. 2018 Dec;7(6):596-610
pubmed: 30687631
Radiother Oncol. 2010 Mar;94(3):274-9
pubmed: 20181401
Med Phys. 2012 Nov;39(11):6621-8
pubmed: 23127056
Radiol Oncol. 2019 Jan 19;53(1):123-130
pubmed: 30661060
Radiother Oncol. 2018 Sep;128(3):411-420
pubmed: 29691075
Radiother Oncol. 2015 Jan;114(1):56-65
pubmed: 25454172
Strahlenther Onkol. 2020 Sep;196(9):749-763
pubmed: 32350554
Radiother Oncol. 2015 Jun;115(3):342-8
pubmed: 26104975
Strahlenther Onkol. 2019 Jan;195(1):21-31
pubmed: 30140943
Front Oncol. 2011 Nov 21;1:43
pubmed: 22649764
Radiother Oncol. 2009 Jan;90(1):66-73
pubmed: 18992950
Strahlenther Onkol. 2019 Nov;195(11):991-1000
pubmed: 31482321
Pathol Oncol Res. 2020 Oct;26(4):2307-2313
pubmed: 32472440
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):515-24
pubmed: 9457842
Radiat Oncol. 2018 Mar 23;13(1):49
pubmed: 29566762
Radiat Oncol. 2017 Sep 11;12(1):151
pubmed: 28893302
Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):196-205.e2
pubmed: 28586960
Breast Care (Basel). 2020 Apr;15(2):136-147
pubmed: 32398982
Med Phys. 1995 Feb;22(2):209-34
pubmed: 7565352
Radiat Oncol. 2016 Feb 27;11:29
pubmed: 26919837
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1041-7
pubmed: 19386428
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1582-6
pubmed: 15817365
Front Oncol. 2016 May 23;6:129
pubmed: 27242967